Brynn E. Marks, MD, MSHPEd
Assistant Professor of Pediatrics (Endocrinology and Diabetes) at the Children's Hospital of Philadelphia
Department: Pediatrics
Contact information
Children's Hospital of Philadelphia
Division of Endocrinology and Diabetes
The Hub for Clinical Collaboration
3501 Civic Center Boulevard
7th Floor, Office 7547
Philadelphia, PA 19104
Division of Endocrinology and Diabetes
The Hub for Clinical Collaboration
3501 Civic Center Boulevard
7th Floor, Office 7547
Philadelphia, PA 19104
Office: 267-426-4925
Publications
Education:
BA (Psychology)
Georgetown University, 2007.
MD
Sidney Kimmel Medical College at Thomas Jefferson University, 2011.
MSHPEd
MGH Institute of Health Professions, 2019.
BA (Psychology)
Georgetown University, 2007.
MD
Sidney Kimmel Medical College at Thomas Jefferson University, 2011.
MSHPEd
MGH Institute of Health Professions, 2019.
Post-Graduate Training
Pediatric Internship , Jefferson Medical College/ Nemours AI duPont Hospital for Children, 2011-2012.
Pediatric Residency, Jefferson Medical College/ Nemours AI duPont Hospital for Children, 2012-2015.
Pediatric Endocrinology Fellowship, Boston Children’s Hospital, 2016-2019.
Permanent linkPediatric Internship , Jefferson Medical College/ Nemours AI duPont Hospital for Children, 2011-2012.
Pediatric Residency, Jefferson Medical College/ Nemours AI duPont Hospital for Children, 2012-2015.
Pediatric Endocrinology Fellowship, Boston Children’s Hospital, 2016-2019.
Description of Clinical Expertise
type 1 diabetes, cystic fibrosis-related diabetes, post-transplant diabetesDescription of Research Expertise
type 1 diabetes, cystic fibrosis-related diabetes, diabetes technology, automated insulin delivery, continuous glucose monitor, insulin pump, medical education, healthcare inequitiesSelected Publications
Galderisi A, Marks BE, DiMeglio LA, de Beaufort C: Endpoints for clinical trials in type 1 diabetes drug development. The Lancet Diabetes and Endocrinology 12(5): 297-299, May 2024.Marks BE, Grundman JB, Meighan S, Monaghan M, Streisand R, Perkins A: Hybrid closed loop systems improve glycemic control and quality of life in historically minoritized youth with diabetes Diabetes Technology & Therapeutics 26(3): 167-175, Mar 2024.
Meighan S, Douvas JL, Rearson A, Squaresky R, Kelly A, Marks BE: The Type of Patient Training Does Not Impact Outcomes in the First 90 Days of Automated Insulin Delivery Use. Diabetes Technology and Therapeutics 2024.
Marks BE, Meighan S, Zehra A, Douvas JL, Rearson A, Suresh R, Brown EA, Wolf RM : Real-World Glycemic Outcomes with Early Omnipod 5 Use in Youth with Type 1 Diabetes Diabetes Technol Ther. Epub ahead of print. , Sept 20. 2023.
Fantasia KL, Demers LB, Steenkamp DW, Modzelewski KL: An Opportunity for Improvement: Evaluation of Diabetes Technology Education Among Adult Endocrinology Training Programs. J Diabetes Sci Technol 17(5): 1274-1283, September 2023.
Wang CH, Bryant BL, Cogen FR, Marks BE, Monaghan M: Preferences for Health Care Professional Interactions Among Adolescents and Young Adults with Type 1 Diabetes Clin Pediatr (Phila) Epub ahead of print, July 2023.
Grundman JB, Chung ST, Estrada E, Podolsky RH, Meyers A, Marks BE: Virtual Learning and Youth-Onset Type 2 Diabetes During the COVID-19 Pandemic. Horm Res Paediatr Epub ahead of print, Jun 2023.
Grundman JB, Perkins A, Monaghan M, Streisand R, Marks BE: Differences in Positive Expectancy of Hybrid Closed Loop (HCL) Insulin Delivery Systems Do Not Explain Racial Differences in HCL Use Journal of Clinical and Translational Endocrinology 32, May 2023.
Grundman JB, Majidi S, Perkins A, Streisand R, Monaghan M, Marks BE: Applying the use of shared medical appointments (SMAs) to improve continuous glucose monitor (CGM) use, glycemic control, and quality of life in marginalized youth with type 1 diabetes: Study protocol for a pilot prospective cohort study. Contemporary Clinical Trials Communications 32, Jan 2023.
Marks BE, Galderisis A, deBeaufort C on behalf of ISPAD: ISPAD Response to FDA “Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products” https://www.regulations.gov/comment/FDA-2023-D-0625-0007 2023.
Contact us
Institute for Diabetes, Obesity and Metabolism
Smilow Center for Translational Research
3400 Civic Center Boulevard, 12th Floor
Philadelphia, PA 19104
Phone: 215-898-0198 | Fax 215-898-5408
Directions
© Trustees of the University of Pennsylvania